Why Is GoodRx Stock Skyrocketing Monday? - GoodRx Holdings ( NASDAQ:GDRX )
Eligible patients can access Ozempic and Wegovy pens for $499/month via GoodRx. Over the past year, nearly 17 million people sought GLP-1 info on GoodRx, up 22%. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.
Why Novo Nordisk Stock Popped Monday
Novo Nordisk stock looks so cheap, any good news at all can make it pop.
HIMS IMPORTANT DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. HIMS between April 29, 2025 and June 23, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health - Hims & Hers Health ( NYSE:HIMS )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options
HIMS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of Hims That A Lawsuit Has Been Filed and Urges Investors to Contact The Firm Before the August 25th Deadline - Hims & Hers Health ( NYSE:HIMS )
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HIMS - Hims & Hers Health ( NYSE:HIMS )
SAN DIEGO, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc.
Shareholders of Hims & Hers Health, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ( "Hims & Hers Health, Inc." or the "Company" ) HIMS of a class action securities lawsuit.
Hims & Hers Stock Plunges 21.3% in 3 Months: Time to Hold or Exit?
HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK and NEW ORLEANS, Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Kahn Swick & Foti, LLC ( "KSF" ) and KSF partner, former Attorney General of Louisiana, Charles C.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health - Hims & Hers Health ( NYSE:HIMS )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
Why Is Hims & Hers Stock Falling Tuesday? - Hims & Hers Health ( NYSE:HIMS ) , Novo Nordisk ( NYSE:NVO )
Novo Nordisk has filed 14 new lawsuits over Wegovy copies, totaling over 130 cases in 40 states. The FDA deadline for compounding Wegovy copies is May 22, unless shortages exist. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → Hims & Hers Health Inc.
Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.
Hims & Hers Health Chief Executive Officer Trades $33.38M In Company Stock - Hims & Hers Health ( NYSE:HIMS )
On August 11, a recent SEC filing unveiled that Andrew Dudum, Chief Executive Officer at Hims & Hers Health HIMS made an insider sell. What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health.
HIMS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. HIMS between April 29, 2025 and June 23, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
HIMS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of Hims That A Lawsuit Has Been Filed and Urges Investors to Contact The Firm - Hims & Hers Health ( NYSE:HIMS )
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
HIMS 2-WEEK DEADLINE ALERT: HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 Following Novo Nordisk Collaboration Termination, Securities Class Action Pending -- Hagens Berman - Hims & Hers Health ( NYSE:HIMS )
SAN FRANCISCO, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- On August 5, 2025, investors in Hims & Hers Health ( NYSE:HIMS ) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized GLP-1 component, a ...
HIMS LAWSUIT ALERT: Levi & Korsinsky Notifies Hims & Hers Health, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ( "Hims & Hers Health, Inc." or the "Company" ) HIMS of a class action securities lawsuit.
Is Most-Watched Stock Hims & Hers Health, Inc. ( HIMS ) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
HIMS DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in...
New York, New York-- ( Newsfile Corp. - August 10, 2025 ) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. ( NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive ( the "Class Period" ) , of the ...
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
The stock remains very volatile.
HIMS IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in...
New York, New York-- ( Newsfile Corp. - August 9, 2025 ) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. ( NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive ( the "Class Period" ) , of the ...
Investors in Hims & Hers Health, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ( "Hims & Hers Health, Inc." or the "Company" ) HIMS of a class action securities lawsuit.
DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - Biohaven ( NYSE:BHVN ) , Centene ( NYSE:CNC )
BENSALEM, Pa., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Should You Buy Hims & Hers Stock on the Dip?
The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects.
Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?
Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks involved in this insightful analysis.
Hims & Hers Redefines Virtual Care With Integrated Tech Platforms
HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.
HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 Following Novo Nordisk Collaboration Termination, Securities Class Action Pending -- Hagens Berman - Hims & Hers Health ( NYSE:HIMS )
SAN FRANCISCO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- On August 5, 2025, investors in Hims & Hers Health ( NYSE:HIMS ) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized GLP-1 component, a ...
These Are the Smartest Growth Stocks to Invest $1,000 in Today
These growth stocks come from completely different industries, but each has something to offer long-term investors.
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK and NEW ORLEANS, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Kahn Swick & Foti, LLC ( "KSF" ) and KSF partner, former Attorney General of Louisiana, Charles C.
HIMS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm - Hims & Hers Health ( NYSE:HIMS )
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
Stock Market Today: Hims & Hers Tumbles 12% on Revenue Miss Despite 73% Growth
Hims & Hers stock fell sharply Tuesday after the company missed Q2 revenue estimates, despite strong growth and reaffirmed guidance.
HIMS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. HIMS between April 29, 2025 and June 23, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
DEADLINE ALERT for RDDT, HIMS, IRBT, and CNC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Hims & Hers Health ( NYSE:HIMS ) , Centene ( NYSE:CNC )
LOS ANGELES, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Hims & Hers Stock Is Trading Lower Tuesday: What's Going On? - Hims & Hers Health ( NYSE:HIMS )
Hims & Hers posts earnings of 17 cents per share, beating the consensus estimate of 14 cents. Subscriber count reaches 2.44 million, up 31% year-over-year, as demand for personalized treatment plans grows. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health - Hims & Hers Health ( NYSE:HIMS )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options
Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say - Hims & Hers Health ( NYSE:HIMS )
Hims & Hers Health reported Q2 revenue of $544.8M, missing consensus of $551.7M. The company reiterated its 2025 revenue and adjusted EBITDA guidance. The market's back, and these 3 income stocks are thriving. See them here→
Why Hims & Hers Health Stock Just Dropped
Hims & Hers stock just got cheaper -- and it's still too expensive to buy.
HIMS CLASS ACTION: Hims & Hers Health, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by August 25 Legal Deadline ( NYSE:HIMS ) - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. HIMS and certain of the Company's senior executives for potential violations of the federal securities laws.
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On? - Hims & Hers Health ( NYSE:HIMS ) , Eli Lilly ( NYSE:LLY )
Hims & Hers Health Inc. HIMS plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
PLTR, HIMS, AEO, JOBY, AMD: 5 Trending Stocks Today - Advanced Micro Devices ( NASDAQ:AMD ) , American Eagle Outfitters ( NYSE:AEO )
Major U.S. indices ended Monday in the green with the Dow Jones Industrial Average rising 1.3% higher at 44,173.64 and the S&P 500 gaining nearly 1.5% to 6,329.94. The tech-heavy Nasdaq shot up 1.95% to 21,053.58.
Hims & Hers ( HIMS ) Q2 Revenue Jumps 73%
Hims & Hers Health ( NYSE:HIMS ) , a direct-to-consumer digital health platform focusing on telehealth, subscription medications, and personalized care, released its second quarter 2025 results on August 4, 2025. The headline news: GAAP revenue grew sharply to $544.8 million, up 73% year over ...
Selloff? What Selloff? Monday Market Rebound
Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.
Hims & Hers Health, Inc. ( HIMS ) Misses Q2 Earnings and Revenue Estimates
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -5.56% and -1.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers stock falls 10% on revenue miss
In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart.
Hims & Hers Tumbles On Q2 Miss, Highlights Growth Prospects - Hims & Hers Health ( NYSE:HIMS )
Hims & Hers Health reports second-quarter revenue of $544.83 million, missing analyst estimates of $549.83 million. The company reports second-quarter earnings of 17 cents per share, beating estimates of 14 cents per share. The market's back, and these 3 income stocks are thriving. See them here→
Hims & Hers Health, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - HIMS - Hims & Hers Health ( NYSE:HIMS )
NEW YORK, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. HIMS. Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
Hims & Hers Health, Inc. ( HIMS ) - Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo's Termination of Collaboration With HIMS Triggers Securities Class Actions -- Hagens Berman
SAN FRANCISCO, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- This latest development follows an announcement by Novo Nordisk on June 23, 2025, the Danish maker of the FDA-approved weight-loss medication Wegovy® ( a GLP-1 treatment for obesity ) , that it terminated its collaboration with Hims & Hers due ...
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Should First Trust Mid Cap Growth AlphaDEX ETF ( FNY ) Be on Your Investing Radar?
Style Box ETF report for ...
